ArticleBMC microbiology2025
Prevalence and molecular characterisation of multi-drug resistant ST11 hypervirulent Klebsiella pneumoniae in a teaching hospital.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Phenotype and molecular characterization of K1-ST700 hypervirulent Klebsiella pneumoniae isolated from bone marrow aspirate of a patient with multi-system infection.BMC microbiology · 2026Article
- Genomic analysis of virulence and antimicrobial resistance in Klebsiella isolates from farmed sika deer.BMC genomics · 2026Article
- The dual threat of hypervirulent and multidrug-resistantFrontiers in microbiology · 2026Review
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Distribution Features and Antimicrobial Resistance Trends of Clinical Pathogens: A Retrospective Study in a Tertiary Teaching Hospital in East China (2020-2024).Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInfections caused by carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-HVKP) pose a critical challenge in clinical management due to limited treatment options and high mortality. Elucidating their virulence determinants and resistance mechanisms is essential for optimizing antimicrobial strategies and improving patient outcomes.
methodsWe conducted a retrospective analysis of 102 carbapenem-resistant CRKP strains. Antimicrobial susceptibility testing was performed using the broth microdilution method, and resistance genotypes were characterized via PCR and Sanger sequencing. Virulence factors were identified through genomic sequencing and validated in a murine survival model (n = 6 mice per strain). Conjugation assays were performed to assess the transferability of resistance and virulence genes, with recipient strain E. coli J53, and transfer events were confirmed by PCR.
resultsCRKP strains were predominantly derived from sputum-, urine- and blood-specimens. Patients with CRKP infections predominantly had pulmonary infections. CRKP exhibited high resistance to other β-lactam antibiotics, mainly due to the presence of bla
conclusionsThese findings reveal that carbapenems in combination with aminoglycosides and quinolones may not be an effective option for the treatment of CRKP infections. Furthermore, the virulence and resistance genes may spread rapidly, which posing a public health risk and a significant threat to clinical care. Therefore, it is necessary to further strengthen hospital infection monitoring, prevention and control measures and to provide strict management and training on the rational use of antimicrobial agents in intensive care units.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.